Design Therapeutics (NASDAQ:DSGN – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.02, FiscalAI reports.
Design Therapeutics Stock Performance
NASDAQ DSGN opened at $12.18 on Monday. The company has a market cap of $760.76 million, a P/E ratio of -10.15 and a beta of 1.63. The business’s 50 day moving average price is $12.46 and its 200-day moving average price is $11.70. Design Therapeutics has a fifty-two week low of $3.76 and a fifty-two week high of $17.25.
Institutional Trading of Design Therapeutics
A number of institutional investors have recently bought and sold shares of DSGN. Invesco Ltd. increased its position in Design Therapeutics by 26.8% during the second quarter. Invesco Ltd. now owns 14,364 shares of the company’s stock valued at $48,000 after acquiring an additional 3,033 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Design Therapeutics by 69.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,377 shares of the company’s stock worth $48,000 after acquiring an additional 2,618 shares during the last quarter. Public Employees Retirement System of Ohio purchased a new position in shares of Design Therapeutics during the 4th quarter worth about $67,000. Jane Street Group LLC purchased a new position in shares of Design Therapeutics during the 1st quarter worth about $70,000. Finally, Bank of America Corp DE grew its holdings in Design Therapeutics by 11.1% during the 2nd quarter. Bank of America Corp DE now owns 24,625 shares of the company’s stock valued at $83,000 after purchasing an additional 2,459 shares during the last quarter. 56.64% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Check Out Our Latest Report on DSGN
Design Therapeutics Company Profile
Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders.
Read More
- Five stocks we like better than Design Therapeutics
- 3 Low-Volatility Plays Quietly Making a Name For Themselves
- ASML’s Dividend Growth Adds a Quiet Income Angle to Its AI Chip Story
- 2 Consumer Staples Stocks Giving Investors a Break From the AI Trade
- 3 Fixed-Income ETFs Show Why Yield Is Only Part of the Income Story
Receive News & Ratings for Design Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Design Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
